Biological treatments in allergy: prescribing patterns and management of hypersensitivity reactions - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Journal of Allergy and Clinical Immunology: In Practice Année : 2021

Biological treatments in allergy: prescribing patterns and management of hypersensitivity reactions

Bernard Yu-Hor Thong

Résumé

Biological agents (BA) are emerging as potential effectivetreatment for allergic and hypersensitivity disorders (A/H). Fourmain classes of BA are now (May 2020) approved by US Foodand Drug Administration and European Medicines Agency forA/H: anti-IgE (omalizumab),1 anti-IL5 (mepolizumab, reslizu-mab),2 anti-IL4/13 (dupilumab),3 and anti-IL5R (benralizu-mab).4 Hypersensitivity reactions (HSR) due to BA can occurwith different severity degrees, which hamper their use. Newtypes of HSR have been reported with lack of standardized andguided allergy workup

Domaines

Allergologie
Fichier principal
Vignette du fichier
S2213219820311983.pdf (408.91 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03231340 , version 1 (10-03-2023)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Leyla Barakat, Maria Jose Torres, Elizabeth Phillips, Marco Caminati, Yoon-Seok Chang, et al.. Biological treatments in allergy: prescribing patterns and management of hypersensitivity reactions. Journal of Allergy and Clinical Immunology: In Practice, 2021, 9 (3), pp.1396-1399.e2. ⟨10.1016/j.jaip.2020.10.044⟩. ⟨hal-03231340⟩
104 Consultations
13 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More